EGFR and breast cancer: There are six combinations between miR-326 and drugs with significant interactions on BC viability: LEE011, BYL719, AZD5363, SCH772984, all already seen for miR-126, Gefitinib and Erlotinib, two epidermal growth factor receptor (EGFR) tyrosine kinases inhibitors.